Brief: Crinetics Announces First Patient Dosed In Phase 1/2 Trial Evaluating Crn09682
03/12/2025 13:07
Dec 3 (Reuters) - Crinetics Pharmaceuticals Inc CRNX.O: CRINETICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 TRIAL EVALUATING CRN09682 FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND OTHER SOMATOSTATIN RECEPTOR 2-EXPRESSING TUMORS Source text: ID:nGNEbMbDXd Further company coverage: CRNX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crinetics Pharmaceuticals
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Crinetics Q2 revenue jumps on PALSONIFY launch, withdraws guidance
Brief: Crinetics Pharmaceuticals Q2 Net Income USD -120.855 Million